KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R01 CA221158
NCI NIH HHS
Grant: R01 CA224493
National Institutes of Health
Grant: R01 CA221158, R01 CA224493, R01 CA240952
NCI NIH HHS
Grant: R01 CA240952
National Institutes of Health
Grant: 7R01CA221158-02
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
European Commission
Grant: 221158
Investigating the neural correlates of working memory capacity using functional magnetic resonance imaging and transcranial magnetic stimulation
National Institutes of Health
Grant: 1R01CA240952-01A1
Targeting NQO1+ tumor to trigger innate and adaptive immunity
National Institutes of Health
Grant: 5R01CA224493-02
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs
FWCI
0.46
Citation Percentile
0.6%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals